November 19, 2018 07:16 AM ESTUpdated 10:57 AM
Deals

Tesaro stock soars on an­oth­er re­port the PARP play­er is ex­plor­ing a sale

ENDPOINTS

At some point some­body might buy can­cer drug­mak­er Tesaro $TSRO, but un­til then it looks like in­vestors will be sub­ject­ed to a seem­ing­ly end­less ar­ray …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times